Lehnen joins Watson to help with Actavis
This article was originally published in Scrip
Watson Pharmaceuticals has appointed Dr Marc Lehnen to the newly created position of senior vp, global integration management, in light of the company's intention to acquire Swiss firm Actavis. Dr Lehnen will head up the global integration management office at Watson which will focus on planning and implementing the integration of Actavis. He will join Watson on 1 July following ten years with McKinsey & Company, most recently as a partner.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.